SCHEMBL31522914

SCHEMBL31522914

CC(F)(F)c1ncc(C(=O)O)c(N)c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ GABRP O00591 3/20 0.41
▸ GABRD O14764 3/20 0.41
▸ GABRA1 P14867 3/20 0.41
▸ GABRB1 P18505 3/20 0.41
▸ GABRG2 P18507 3/20 0.41
▸ GABRB3 P28472 3/20 0.41
▸ GABRA5 P31644 3/20 0.41
▸ GABRA3 P34903 3/20 0.41
▸ GABRA2 P47869 3/20 0.41
▸ GABRB2 P47870 3/20 0.41
▸ GABRA4 P48169 3/20 0.41
▸ GABRE P78334 3/20 0.41
▸ GABRA6 Q16445 3/20 0.41
▸ GABRG1 Q8N1C3 3/20 0.41
▸ GABRG3 Q99928 3/20 0.41
▸ GABRQ Q9UN88 3/20 0.41
▸ HAVCR2 Q8TDQ0 1/20 0.37
▸ ASPH Q12797 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31523480 0.87 KDM4E (0.41) KDM4EKMT2AGABRPGABRDGABRA1
SCHEMBL31523667 0.83 CFTR (0.40) KDM4EKMT2AALDH1A1HSD17B10MAPT
SCHEMBL31522964 0.77 KDM4E (0.49) KDM4EKMT2AGABRPGABRDGABRA1
SCHEMBL18988808 0.73 KDM4E (0.56) KDM4EASPHKDM8HSD17B10KDM4A
SCHEMBL9803929 0.73 KDM4E (0.49) KDM4EKMT2AGABRPGABRDGABRA1
SCHEMBL31523306 0.73 KDM4E (0.38) KDM4EKMT2AGABRPGABRDGABRA1
SCHEMBL31523460 0.73 HAVCR2 (0.39) KDM4EKMT2AGABRPGABRDGABRA1
SCHEMBL22208176 0.73 HAVCR2 (0.47) KDM4EKMT2AGABRPGABRDGABRA1
SCHEMBL31523105 0.73 MBOAT4 (0.30) —
SCHEMBL30064870 0.73 HAVCR2 (0.47) KDM4EKMT2AGABRPGABRDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-11-13 — — US disclosed
WO-2025054488-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2025-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES WRN, RECQL, BLM KDM4E 3487/4885KMT2A 2611/4885GABRP 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback